Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells

International Journal of Hematology

Volumn 94, Issue 1, 2011, Pages 63-70

  Cui, Qu ^a   Shibata, Hironobu ^a,b   Oda, Asuka ^a   Amou, Hiroe ^a   Nakano, Ayako ^a   Yata, Kenichiro ^a   Hiasa, Masahiro ^a,c   Watanabe, Keiichiro ^a,c   Nakamura, Shingen ^a   Miki, Hirokazu ^a   Harada, Takeshi ^a   Fujii, Shiro ^a   Kagawa, Kumiko ^a   Takeuchi, Kyoko ^a   Ozaki, Shuji ^a,b   Matsumoto, Toshio ^a   Abe, Masahiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Immunotherapy; Multiple myeloma; Osteoclast; V 9V 2 T cell; Zoledronic acid

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOPONTIN; RECOMBINANT INTERLEUKIN 2; STROMAL CELL DERIVED FACTOR 1; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE DESTRUCTION; BONE LESION; CELL EXPANSION; CELL INTERACTION; CELL MIGRATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MULTIPLE MYELOMA; MYELOMA; OSTEOCLAST; OSTEOCLASTOGENESIS; T LYMPHOCYTE RECEPTOR GENE; T LYMPHOCYTE SUBPOPULATION; TARGET CELL;

CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INTERLEUKIN-2; MULTIPLE MYELOMA; OSTEOCLASTS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 79960105452     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0885-9     Document Type: Conference Paper

References (32)

1. SJ Choi JC Cruz F Craig H Chung RD Devlin GD Roodman 2000 Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood 96 671 675 (Pubitemid 30463390)
2. JH Han SJ Choi N Kurihara M Koide Y Oba GD Roodman 2001 Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand Blood 97 3349 3353
3. M Abe K Hiura J Wilde K Moriyama T Hashimoto S Ozaki 2002 Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma Blood 100 2195 2202 (Pubitemid 35001256)
4. T Hashimoto M Abe T Oshima H Shibata S Ozaki D Inoue 2004 Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma Br J Haematol 125 38 41 (Pubitemid 38453275)
5. M Abe K Hiura S Ozaki S Kido T Matsumoto 2009 Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production J Bone Miner Metab 27 16 23
6. M Abe K Hiura J Wilde A Shioyasono K Moriyama T Hashimoto 2004 Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood 104 2484 2491 (Pubitemid 39331851)
7. M Abe S Kido M Hiasa A Nakano A Oda H Amou 2006 BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma Leukemia 20 1313 1315 (Pubitemid 43905843)
8. Y Ge F Zhan B Barlogie J Epstein J Shaughnessy Jr S Yaccoby 2006 Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival Br J Haematol 133 83 92 (Pubitemid 43327202)
9. A Pennisi X Li W Ling S Khan D Gaddy LJ Suva 2009 Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease Br J Haematol 145 775 787
10. S Yaccoby 2010 Advances in the understanding of myeloma bone disease and tumour growth Br J Haematol 149 311 321
11. S Yaccoby MJ Wezeman A Henderson M Cottler-Fox Q Yi B Barlogie 2004 Cancer and the microenvironment: myeloma-osteoclast interactions as a model Cancer Res 64 2016 2023 (Pubitemid 38339448)
12. M Brandes K Willimann B Moser 2005 Professional antigen-presentation function by human gammadelta T cells Science 309 264 268 (Pubitemid 40967855)
13. AC Hayday 2009 Gammadelta T cells and the lymphoid stress-surveillance response Immunity 31 184 196
14. M Bonneville RL O'Brien WK Born 2010 Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity Nat Rev Immunol 10 467 478
15. M Bonneville JJ Fournie 2005 Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites Microbes Infect 7 503 509 (Pubitemid 40603450)
16. K Thompson J Rojas-Navea MJ Rogers 2006 Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway Blood 107 651 654 (Pubitemid 43076390)
17. F Miyagawa Y Tanaka S Yamashita B Mikami K Danno M Uehara 2001 Essential contribution of germline-encoded lysine residues in Jgamma1.2 segment to the recognition of nonpeptide antigens by human gammadelta T cells J Immunol 167 6773 6779 (Pubitemid 33144167)
18. HJ Gober M Kistowska L Angman P Jeno L Mori G De Libero 2003 Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells J Exp Med 197 163 168 (Pubitemid 36152311)
19. E Espinosa C Belmant F Pont B Luciani R Poupot F Romagne 2001 Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells J Biol Chem 276 18337 18344
20. Y Tanaka CT Morita E Nieves MB Brenner BR Bloom 1995 Natural and synthetic non-peptide antigens recognized by human gamma delta T cells Nature 375 155 158
21. S Yamashita Y Tanaka S Tsutsumi H Aburatani N Minato S Ihara 2005 Analysis of mechanism for human gammadelta T cell recognition of nonpeptide antigens Biochem Biophys Res Commun 334 349 360 (Pubitemid 40982375)
22. M Corvaisier A Moreau-Aubry E Diez J Bennouna JF Mosnier E Scotet 2005 V gamma 9V delta 2 T cell response to colon carcinoma cells J Immunol 175 5481 5488 (Pubitemid 41456435)
23. H Kobayashi Y Tanaka J Yagi Y Osaka H Nakazawa T Uchiyama 2007 Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study Cancer Immunol Immunother 56 469 476 (Pubitemid 46204533)
24. V Kunzmann E Bauer J Feurle F Weissinger HP Tony M Wilhelm 2000 Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma Blood 96 384 392 (Pubitemid 30463353)
25. R Mahtani R Khan M Jahanzeb 2011 The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer Clin Lung Cancer 12 26 32
26. M von Lilienfeld-Toal J Nattermann G Feldmann E Sievers S Frank J Strehl 2006 Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells Clin Exp Immunol 144 528 533 (Pubitemid 43799937)
27. A Thedrez C Sabourin J Gertner MC Devilder S Allain-Maillet JJ Fournie 2007 Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev 215 123 135 (Pubitemid 46212235)
28. M Bonneville E Scotet 2006 Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors Curr Opin Immunol 18 539 546 (Pubitemid 44311448)
29. Y Abe M Muto M Nieda Y Nakagawa A Nicol T Kaneko 2009 Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma Exp Hematol 37 956 968
30. A Saitoh M Narita N Watanabe N Tochiki N Satoh J Takizawa 2008 Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma Med Oncol 25 137 147
31. M Wilhelm V Kunzmann S Eckstein P Reimer F Weissinger T Ruediger 2003 Gammadelta T cells for immune therapy of patients with lymphoid malignancies Blood 102 200 206 (Pubitemid 36759655)
32. A Sabokbar NS Athanasou 2003 Generating human osteoclasts from peripheral blood Methods Mol Med 80 101 111